Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
- 3 April 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 97 (8), 1417-1425
- https://doi.org/10.1007/s00277-018-3311-z
Abstract
The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II trials, without comparative data. We compared the efficacy of two commonly used regimens in routine practice (bendamustine-rituximab (BR) and dexamethasone, rituximab plus cyclophosphamide (DRC)) and evaluated their activity with respect to the patients’ MYD88L265P mutation status. Of 160 consecutive patients, 60 received BR (43 with relapsed/refractory WM) and 100 received DRC (50 had relapsed/refractory WM). In the treatment-naïve setting, overall response rate (ORR) was 93% with BR versus 96% with DRC (p = 0.55). Two-year progression-free survival (PFS) with BR and DRC was 88 and 61%, respectively (p = 0.07). In salvage setting, ORR was 95% with BR versus 87% with DRC, p = 0.45; median PFS with BR was 58 versus 32 months with DRC (2-year PFS was 66 versus 53%; p = 0.08). Median disease-specific survival was not reached with BR versus 166 months with DRC (p = 0.51). The time-to-event endpoints and depth of response were independent of the MYD88 mutation status. Grade ≥ 3 adverse events of both regimens were comparable. A trend for longer PFS was observed with BR although the regimens have comparable toxicities. The activity of BR and DRC appears to be unaffected by patients’ MYD88 mutation status.Keywords
This publication has 34 references indexed in Scilit:
- Clinical Trial Participation among Ethnic/Racial Minority and Majority Patients with Advanced Cancer: What Factors Most Influence Enrollment?Journal of Palliative Medicine, 2013
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopBritish Journal of Haematology, 2012
- IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomasLeukemia, 2012
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- Bendamustine: Rebirth of an Old DrugJournal of Clinical Oncology, 2009
- Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and CyclophosphamideJournal of Clinical Oncology, 2007
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell linesAnti-Cancer Drugs, 1996